TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01828554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Ideal Body Weight to calculate dosage. Cycle 1, Day 8-No drug.~Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug.~Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage.
Study: NCT01651767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Form=suspension, route=oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Form=suspension, route=oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Form=suspension, route=oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Form=suspension, route=oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382
Description: Type=exact number, unit=mg, number=30, 90, 300, 400 or 450, form=suspension, route=oral. Study drug will be administered once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382
Description: Type=exact number, unit=mg, number=30, 90, 300, 400 or 450, form=suspension, route=oral. Study drug will be administered once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382
Description: Type=exact number, unit=mg, number=30, 90, 300, 400 or 450, form=suspension, route=oral. Study drug will be administered once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382
Description: Type=exact number, unit=mg, number=30, 90, 300, 400 or 450, form=suspension, route=oral. Study drug will be administered once or twice daily
Study: NCT02753738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Tablet 10mg, 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, 21 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 3xMR scan (fMRI, DTI, strucutral MRI)
Description: 3 Tesla PRISMA MAGNETOM MR scanner; performed at baseline, after 21 days of performing learning paradigms and after 21 days of drug/placebo treatment and re-learning paradigms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3xMR scan (fMRI, DTI, strucutral MRI)
Description: 3 Tesla PRISMA MAGNETOM MR scanner; performed at baseline, after 21 days of performing learning paradigms and after 21 days of drug/placebo treatment and re-learning paradigms

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Association learning paradigm
Description: 21 daily internet-based sessions (20min) of learning associations (pairs) of stimuli

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Association learning paradigm
Description: 21 daily internet-based sessions (20min) of learning associations (pairs) of stimuli
Study: NCT02799238

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy 5 days/week for 6 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy 5 days/week for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide daily for 6 weeks followed by 6 cycles 5days/4weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Temozolomide daily for 6 weeks followed by 6 cycles 5days/4weeks
Study: NCT03785535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulation
Description: The active treatment will involve whole-body sensory stimulation with mechanical stimuli of vibrotactile (pallesthetic) type at a relatively high rate, low intensity and long duration administered at sleep time (a total daily duration of 3 h distributed within a period of 2 h at bedtime and 1 h prior to getting up). The intensity will be 30% of power at bedtime and 45% prior to getting up.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vibrotactile stimulation
Description: The active treatment will involve whole-body sensory stimulation with mechanical stimuli of vibrotactile (pallesthetic) type at a relatively high rate, low intensity and long duration administered at sleep time (a total daily duration of 3 h distributed within a period of 2 h at bedtime and 1 h prior to getting up). The intensity will be 30% of power at bedtime and 45% prior to getting up.
Study: NCT04095949

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artichokes
Description: Approximately 200 g of cooked artichokes
Study: NCT05562908

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pedicled
Description: Surgical procedure: A prior marking was made on both sides of the LIMA and its veins with bi-polar technique. Hereafter the LIMA and its veins were dissected free with scissor and forceps. Clips were added to all side branches. When the full length of LIMA was obtained, the LIMA and its veins were divided distally by adding clips on the peripheral part of the vessels and proximately dividing by scissor. A vessel-clamp was placed distally and the pedicled LIMA placed in the jugular cavity with a cloth containing papaverine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical skeletonised
Description: Surgical procedure: The fascia of the LIMA was opened with a scissor. Hereafter the LIMA was dissected free with scissor and forceps, clips on all LIMA side-branches and divided by scissor. When the full length of LIMA was obtained, the LIMA was divided distally by adding clips on the peripheral part of the vessel and proximately dividing by scissor. A vessel-clamp was placed distally, and the skeletonised LIMA placed in the jugular cavity with a cloth containing papaverine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thunderbeat skeletonised
Description: Surgical procedure: With Thunderbeat the fascia of LIMA was opened. The LIMA was dissected free with Thunderbeat including all side-branches. When the full length of the LIMA was obtained, the LIMA was divided distally by adding clips on the peripheral part of the vessel and proximately dividing by scissor. A vessel-clamp was placed distally, and the skeletonised LIMA placed in the jugular cavity with a cloth containing papaverine.
Study: NCT00658931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug treatment with Cymbalta
Description: Drug treatment with Cymbalta
Study: NCT02872792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early mobilisation with cyclo ergometer
Description: Early mobilisation with cyclo ergometer is done daily during hospitalization for sepsis in an Intensive Care Unit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physiotherapy
Description: Standard physiotherapy included passive and active manual mobilization, sitting on bed, sitting in chair, walking

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy
Description: Standard physiotherapy included passive and active manual mobilization, sitting on bed, sitting in chair, walking
Study: NCT00614809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: gefitinib 250mg qd until disease progression or unacceptable toxicity.
Study: NCT00262041

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM conjugate vaccine, adjuvanted

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM conjugate vaccine, unadjuvanted

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY polysaccharide vaccine
Study: NCT03831763

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ColdZyme
Description: ColdZyme® Mouth Spray is a CE-marked medical device with the following composition: glycerol, water, cod trypsin, ethanol (\<1 %), calcium chloride, trometamol and menthol.~ColdZyme® Mouth Spray consists of a 20 ml bottle, pump, spray nozzle and protective cap.
Study: NCT03012672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05717855

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Displaying optic chiasm for screening septooptic dysplasia
Description: Displaying and measuring the width and length of the optic chiasm for screening septooptic dysplasia with ultrasound between 16-20 weeks of gestation
Study: NCT01332578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Present in both test and active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Present in both test and active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Test product
Study: NCT03001219

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-TNF-alpha
Description: Participants will continue their pre-trial anti-TNF-alpha therapy at a stable dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-TNF-alpha
Description: Participants will continue their pre-trial anti-TNF-alpha therapy at a stable dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-TNF-alpha
Description: Participants will continue their pre-trial anti-TNF-alpha therapy at a stable dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-TNF-alpha
Description: Participants will continue their pre-trial anti-TNF-alpha therapy at a stable dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-TNF-alpha
Description: Participants will continue their pre-trial anti-TNF-alpha therapy at a stable dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-TNF-alpha
Description: Participants will continue their pre-trial anti-TNF-alpha therapy at a stable dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Participants will continue their pre-trial methotrexate therapy at a stable dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants will continue their pre-trial methotrexate therapy at a stable dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Participants will continue their pre-trial methotrexate therapy at a stable dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants will continue their pre-trial methotrexate therapy at a stable dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Participants will continue their pre-trial methotrexate therapy at a stable dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants will continue their pre-trial methotrexate therapy at a stable dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive intravenous infusion of placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive intravenous infusion of placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive intravenous infusion of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7123520
Description: Participants will receive intravenous infusion of RO7123520.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7123520
Description: Participants will receive intravenous infusion of RO7123520.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7123520
Description: Participants will receive intravenous infusion of RO7123520.
Study: NCT01425723

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFIXFc
Description: Administered as specified in the treatment arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFIXFc
Description: Administered as specified in the treatment arm.
Study: NCT04002505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concussion and Brain Bleed App (CBB)
Description: Tablet based decision aid that encourages shared decision making with the goal of educating patients to reduce unnecessary CT scans
Study: NCT00446199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5mg DRSP / 0.5mg E2 (BAY86-4891)
Description: One tablet \[0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)
Description: One tablet \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol (E2 0.3mg)
Description: One tablet \[17β-estradiol (E2 0.3mg)\] per day taken orally for 3 cycles (28 days per cycle).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
Study: NCT02426047

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: betaquik®
Description: Participants will add betaquik® (a liquid emulsion of medium chain triglycerides) for a 10 day time interval starting 2 days prior to and encompassing the primary catamenial pattern.
Study: NCT01481909

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rupatadin
Description: 20 mg, 28 days over 60 days
Study: NCT04163640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intra-ovarian platelet rich plasma injection
Description: patients will undergo a transvaginal intra-ovarian platelet rich plasma injection
Study: NCT03176173

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-guided Radiation Therapy
Description: Ablative treatment as 50 Gy in 5 or 10 fractions.~Non-ablative treatment as 27 Gy in 3 fractions, or 40 Gy in 10 fractions.
Study: NCT01011075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: Imatinib (Gleevec) 600 mg/day, oral administration in 4-day pulses(days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Cycle length: 28 days Number of cycles: up to 6
Study: NCT03708965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-141
Description: IV infusion (lyophilized powder)
Study: NCT00946348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol 10 mg or 15 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis
Description: Cannabis cigarette
Study: NCT03867799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Immunotherapy
Study: NCT04232813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol 10 MCG Vaginal Tablet [VAGIFEM]
Description: To insert the tablets the patient must use the applicator provided in the way explained in the prospectus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Promestriene Vaginal
Description: To insert the cream the patient must use the applicator provided in the way explained in the prospectus.
Study: NCT02171676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Study: NCT02799030

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BF-200 ALA 1%
Description: topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF-200 ALA 1%
Description: topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BF-200 ALA 3%
Description: topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF-200 ALA 3%
Description: topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BF-200 ALA 10%
Description: topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF-200 ALA 10%
Description: topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
Study: NCT01264042

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate
Description: 60 mg with 200 mL water, single administration
Study: NCT00570882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib 2/1
Description: Sunitinib 50 mg PO 2 weeks followed by 1 week rest
Study: NCT02753738

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Association re-learning paradigm
Description: 21 daily internet-based sessions (20min) of learning new associations (pairs) of stimuli performed during escitalopram/placebo treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Association re-learning paradigm
Description: 21 daily internet-based sessions (20min) of learning new associations (pairs) of stimuli performed during escitalopram/placebo treatment
Study: NCT02009228

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovarian cystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovarian cystectomy
Study: NCT02831361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemigliptin placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diet/exercise questionnaire
Description: doing exercise with about intermediate intensity(50\~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regualr diet without greater changes in life style as much as possible during the whole study period.~the questionnaire regarding diet/exercise will be collected at -week2, week 1 week 7, week 13, week 19, week 25

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Diet/exercise questionnaire
Description: doing exercise with about intermediate intensity(50\~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regualr diet without greater changes in life style as much as possible during the whole study period.~the questionnaire regarding diet/exercise will be collected at -week2, week 1 week 7, week 13, week 19, week 25
Study: NCT03210454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smallholder Marketing
Description: The smallholder marketing intervention involves product purchasing (e.g., bananas, beans, goats, eggs) from smallholder farmers' associations through WFP's large procurement procedures. WFP is will also provide technical training on topics such as sustainable farming practices, quality control, and business practices.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smallholder Marketing
Description: The smallholder marketing intervention involves product purchasing (e.g., bananas, beans, goats, eggs) from smallholder farmers' associations through WFP's large procurement procedures. WFP is will also provide technical training on topics such as sustainable farming practices, quality control, and business practices.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intimate Partner Violence (IPV) Prevention Training
Description: IPV prevention training involves 24 hours of gender training (gender equality and rights, economic empowerment, gender-based violence prevention), and 8 hours of nutrition and food security training (with a focus on gender).
Study: NCT00147485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-024322
Study: NCT05334199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodegradable stent
Description: Bronchoscopic placement of biodegradable stent in patients with airway complications after lung transplant
Study: NCT02995460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interval training
Description: 4x4 high intensity interval training
Study: NCT03498768

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Subjects will be invited to complete a detailed questionnaire regarding personal information, known risk factors for lung cancer and psychological status.
Study: NCT00373529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Induction cycle 1: cycle 1 of clofarabine 30 mg/m\^2/day as a 1-hour intravenous infusion for 5 consecutive days.~Reinduction (cycle 2) and/or Consolidation cycles (cycles 2-6): cycles repeated minimally every 28 days, of clofarabine 20 mg/m\^2/day as a 1-hour intravenous infusion for 5 consecutive days.